Xenon Pharmaceuticals to Participate in Upcoming Investor Conferences
Get Alerts XENE Hot Sheet
Join SI Premium – FREE
BURNABY, British Columbia, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a clinical stage biopharmaceutical company, today announced that Dr. Simon Pimstone, Xenon's Chief Executive Officer, will participate in the following virtual investor conferences:
- William Blair Biotech Focus Conference 2020 | Panel 4: New Therapies Impacting the Epilepsy Treatment Landscape on Thursday, August 6, 2020 at 12:00 pm ET
- 2020 Wedbush PacGrow Healthcare Conference on Tuesday, August 11, 2020 at 3:30 pm ET
The above listed dates and times are subject to change. Details on company presentations and webcasts can be found on the “Investors” section of Xenon's website at www.xenon-pharma.com. All webcasts will be posted for replay following the event for 30 days.
About Xenon Pharmaceuticals Inc.
We are a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy. For more information, please visit www.xenon-pharma.com.
“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.
Investor/Media Contact:
Jodi Regts
Xenon Pharmaceuticals Inc.
Phone: 604.484.3353
Email: [email protected]
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Savour the Last Stretch of Summer with $5 Movies and Popcorn
- Three Aptean Nominees Honored in 2026 Women in Supply Chain Forum™ Awards
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
William BlairSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share